Centers | ||
|
|
|
Edinburgh Drug Discovery | test | VMCC, University of Michigan |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
sfgd |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all |
No EVENTS for listing |
No Job Posts |
